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Metastases are the cause of 90% of human cancer deaths. Cancer in situ can usually 
be effectively removed by surgery. Once cancer cells disseminate from the original 
site and start to circulate in blood, lymph, or other body fluids, the disease becomes 
almost incurable. Here we show that cancer cells in a non-adherent, 3-dimentional 
growth pattern are highly drug resistant compared to their adherent counterparts 
that grow in monolayer, attaching to the wall of tissue culture plates. The non-
adherent cancer cells retain the adhering potential and can attach to an appropriate 
surface to reacquire adherent phenotype. Once the non-adherent cancer cells 
become attached, they regain drug response, similar to the original adherent cells. A 
significant increase in the expression of CD133, CD44, Nanog, survivin, and 
thymidylate synthase was observed in the non-adherent cancer cells compared to 
their adherent counterparts, which may underlie the mechanisms of multidrug 
resistance of the cells. Since the non-adherent cancer cells cultured in vitro resemble 
the circulating metastatic cells in vivo in that both cells exhibit suspended non-
adherent phenotype, possess re-attaching potential, and are highly drug resistant, 
we suggest that circulating metastatic cells can attach to an appropriate surface to 
gain adherent phenotype and subsequently acquire drug sensitivity. We propose 



































matrix and collagen that mimic the structural framework of real human tissues to 
which cells can attach and grow may be able to stabilize the circulating metastatic 
cells. Once the metastatic cells undergo attachment and become adherent, they gain 
drug sensitivity and can be killed by anticancer drugs that are either administered 
to the blood or conjugated to the devices.  
      The cancer stem cells (CSCs) have been highlighted lately, due to the opinion that 
these CSCs are the culprits for therapeutic resistance, metastasis, and recurrence of the 
diseases, and therefore, might be selected as the target of treatment1-4. Of the many 
properties that the CSCs possess, two characteristics came to our attention, i.e., non-
adherent, 3-dimentional growth phenotype and high drug resistance. While working on 
the isolation and maintenance of CSCs, we found that anticancer drug resistance of the 
cancer cells was associated with their suspended, non-adherent growth pattern.  
      We isolated CD133 positive cells from human colon carcinoma cell lines CBS, 
Moser, HCT113, Fet, Caco-2, and SW480 cells using anti-CD133 antibody and Magnetic 
Cell Separation Rack. We also isolated CD44 positive cells from human breast carcinoma 
cell lines MDA-MB-231, MDA-MB-435, MCF-7, HCC1937, HCC1806, and Hs578T 
cells using anti-CD44 antibody and the same device. The isolated-cells were cultured in 
stem-cell culture medium (StemPro medium: DMEM/F-12/GlutaMax, StemPro Growth 
Supplement, 1.8% BSA, FGF, Nodal, Noggin, and 2-Mercaptoethanol) to retain the cells 
in an undifferentiated stemness status. The isolated cells growing in the StemPro medium 
exhibited a suspended, non-adherent, 3-dimentional spherical growth phenotype 
compared to their adherent counterparts in the regular medium (5% FBS/SMEM) that 



































colon carcinoma CBS cells and breast carcinoma MDA-MB-231 cells were shown as 
representatives (Fig 1a and 1b). Later on we accidently found that the adherent phenotype 
could be acquired to the cells by simply placing the parental cells in a basic serum-free 
medium (DMEM/F-12/GlutaMax + 1.8% BSA) (Fig 1a-iii and b-iii). Furthermore, we 
found that the cancer cells acquired similar non-adherent morphology when cultured in 
regular medium (5% FBS/SMEM) but in an Ultra Low Attachment Surface (ULAS) plate 
(polystyrene coated with neutral charged, hydrophilic hydrogel) (Fig 1a-iv and b-iv). All 
the non-adherent cells proliferated in a fast pace and were fully viable, determined by the 
Vi-CELL XR Cell Viability Analyzer (Beckman Coulter), which pre-stain the cells to 
detect the viable cells from the total cell counting. We have also tested normal human 
colon epithelial cell lines NCM460 and NCM356 cells, as well as normal human breast 
cell line MCF-10A cells for their suspended non-adherent growth pattern. None of the 
cells survived in a non-adherent growth condition (data not shown), indicating that the 
anchorage-independent, non-adherent phenotype is unique to cancer cells. 
      With further study, we found that the non-adherent cells—from either the isolated 
cells in StemPro medium, the non-adherent cells in the basic serum-free medium, or the 
non-adherent cells in the ULAS plates—were equally resistant to anticancer drugs. As it 
is shown in Fig 2, the non-adherent CBS cells were almost completely resistant to 
fluorouracil (5-FU)—the drug of choice for colon cancer—at a dose of as high as 300 
μM, though it killed more than 80% of the adherent cells in monolayer attachment 
growth (Fig 2a). Similarly, the non-adherent MDA-MB-231 cells were highly resistant to 
paclitaxel—the drug of choice for breast cancer—at a dose of 8 μM, while it killed 



































resistant. As it is shown in Fig 2c, the non-adherent CBS cells were resistant to all the 
FOLFIRI (5-FU, leucovorin, and SN-38)—the regimen of choice for colon cancer, the 
mitomycin C (MMC), and the paclitaxel. Similar results were obtained with all of the 
aforementioned cells tested.  
      Although non-adherent cancer cells exhibit a suspended growth pattern, they have not 
lost attachment potential. Once the cells were placed to a regular medium (5% 
FBS/SMEM) in normal tissue culture plates (polystyrene with negatively charged, 
hydrophilic surface), the cells quickly reacquired attachment to the wall of the plates and 
grew in a monolayer attachment pattern similar to the adherent cells (Fig 1c). Moreover, 
the re-attached cancer cells re-gained response to anticancer drugs just as the adherent 
cells (Fig 3).   
      We don’t know why the non-adherent cancer cells are highly resistant at this moment. 
We did see, however, that the non-adherent cancer cells expressed a high level of so-
called “cancer stem cell markers” such as CD133 and CD44 compared to the adherent 
cells (Fig 4) 5-7. Nanog, a transcription factor functioning in maintaining embryo stem 
cells in the undifferentiated state8, survivin, an anti-apoptotic molecule9,10, and 
thymidylate sythase (TS), a key enzyme involved in the de novo synthesis of DNA which 
circumvents the efficacy of 5-FU11,12, are also significantly up-regulated in the non-
adherent cells (Fig 4a). Although the results suggested that the non-adherent cancer cells 
possess some CSCs properties that might have been the underlying mechanism of the 
drug resistance of the cells, the relationship of the non-adherent cancer cells with CSCs 
are far from understood. CSCs are defined as a distinct subpopulation of cancer-initiating 



































general cancer cell population, only CSCs possess the stem cell-like characteristics 
including undifferentiated status, drug resistance, tumorigenesity, expression of stem cell 
markers, self-renewal, and metastasis1,2,13,14. This CSC theory is, however, not 
unchallenged. Some studies have reported that all cells from tumours are equally 
tumorigenic15-17. It seems that our results support the latter by showing that the non-
adherent cancer cells, prepared from either the isolated stem cell marker-expressing cells 
or the general cell population in suspended growth pattern, are equally expressing stem 
cell markers and highly drug resistant. Moreover, once the non-adherent cells underwent 
attachment, the up-regulated CD133 and CD44 quickly reversed to the levels of adherent 
cells (Fig 4b). These results may suggest that some of the stem cells’ characteristics, or 
specifically the drug resistance of cancer cells, are more likely determined by the 
microenvironment-controlled cell growth patterns rather than by the bone fide cancer 
stem cells.  
      Several conclusions can be drawn from the results described above. (1) All the cancer 
cells tested can grow in an anchorage-independent, non-adherent manner. (2) Non-
adherent cancer cells are highly resistant. (3) Non-adherent cancer cells still possess 
adherent potential and can quickly reacquire the adherent phenotype when an appropriate 
surface and a serum-containing medium are provided. (4) Re-attached cancer cells 
possess the same response to anticancer drugs that the original adherent cells do. It is 
noteworthy to point out that although we only showed data from two representative cell 
lines in the article, we have obtained similar results from all the aforementioned cell 
lines, indicating that the phenomena observed are not specific to individual cell lines but 



































tissues that we have not yet tested. We propose that the properties that the non-adherent 
cancer cells possess in vitro may also apply to cancer cells in vivo. The non-adherent 
cancer cells resemble circulating metastatic cancer cells in that both cells survive in an 
anchorage-independent, non-adherent manner and both cells possess the potential of re-
attachment when a favourable condition is introduced. Like the non-adherent cells that 
are more resistant than their adherent counterparts, the circulating metastatic cells are 
also resistant to anticancer drugs18. Turning metastatic cancer cells from a non-adherent 
to an adherent phenotype may, therefore, increase the sensitivity of the non-adherent 
metastatic cells to anticancer drugs, as what happened in the in vitro cell culture 
condition. We have known from this study that an appropriate attachment surface and a 
serum-containing medium are the two requirements for non-adherent cells to undergo 
attachment. In a real human body, the serum can be ignored since body fluids contain a 
similar serum as FBS. Therefore, introducing an appropriate surface is the key issue to 
fulfilling this purpose. In the condition of in vitro cell culture, cell attachment proteins 
bind well to the negatively charged, hydrophilic surface of the polystyrene wall of the 
tissue culture plates. In real human tissues, the structural framework formed by 
fibroblasts and their synthesized extracellular matrix and collagen provide surface for 
cells to attach and grow. If we introduce devices or micro-particles with a surface coated 
and conjugated with all the necessary attachment materials, we may be able to adsorb the 
circulating cancer cells to the attachment surface. As we have already known from the in 
vitro tests, adherent cancer cells are much more sensitive to anticancer drugs. Thus, a 
standard dose of anticancer drugs in the blood or conjugated on the attachment surface 



































fluids would not attach to the attachment surface since blood cells are naturally 
anchorage-independent and do not possess the potential of adhesion.  
      The non-adherent cancer cell model may also be applied in high-throughput screening 
of agents targeting CSCs or resistant cancer cells. In principle, the application of 
automated screening technologies could facilitate the identification of agents that kill 
CSCs or resistant cancer cells. However, the screening depends on the ability to 
propagate stable, highly enriched populations of CSCs in vitro, which is not currently 
possible for the CSCs of solid tumours4. The non-adherent cancer cells, although not yet 
being fully determined for their CSCs properties, do possess CSC characteristics of high 
drug resistance; the cells are also easy to prepare and maintain. Therefore, the non-
adherent cancer cell model may well apply for such purposes.  
 
METHODS 
Cell culture.  Human colon cancer cell lines CBS, Moser, HCT113, Fet, Caco-2, and 
SW480 cells and human breast cancer cell lines MDA-MB-231, MDA-MB-435, MCF-7, 
HCC1937, HCC1806, and Hs578T cells were maintained in SMEM medium (MEM 
medium supplemented with sodium bicarbonate, peptone, vitamins, amino acids, and 5% 
fetal bovine serum (FBS) (Sigma, St. Louis, MO). CD133(+) colon carcinoma cells and 
CD44(+) breast carcinoma cells were maintained in StemPro medium (1×DMEM/F-
12/GlutaMax, 1×StemPro Growth Supplement, 1.8% BSA, 8 ng/ml FGF, 10 ng/ml 
Nodal, 10 ng/ml Noggin, and  0.1 mM 2-Mercaptoethanol) (Invitrogen Co.). Preparation 
of the non-adherent cancer cells in the basic serum-free medium: the cancer cells were 



































then placed and maintained in the basic serum-free medium (1×DMEM/F-12/GlutaMax + 
1.8% BSA). Preparation of the non-adherent cancer cells in ULAS flask: the cancer cells 
were detached using 0.25% trypsin-EDTA solution and washed with cold 1×PBS buffer 
and then placed and maintained in SMEM medium in ULAS flasks (polystyrene coated 
with neutral charged, hydrophilic hydrogel) (Corning Inc.) 
Magnetic cell separation.  CD133(+) colon cancer cells were labeled with anti-CD133 
antibody (Miltenyi Biotec) and CD44(+) breast cancer cells were labeled with anti-CD44 
antibody (Cell Signaling), followed by incubation with magnetic-beads conjugated goat 
anti-mouse secondary antibody (New England BioLab) and separation of the labeled cells 
from the unlabeled cell population using a Magnetic Separation Pack (New England 
BioLab).  
Morphology.  OLYMPUS CKX41SF microscope connected with OLYMPUS DP-12 
camera (Olympus Co., Japan) were used to analyze and record the morphology of the 
cells.  
Cell viability assays. A Vi-CellTM XR Cell Viability Analyzer (Beckman Coulter, Inc., 
Fullerton, CA) was used to determine the number of viable cells in a suspension after 
exposure to the anticancer drugs indicated in the figures. 
Western analysis.  Standard Western blot procedures were performed.  
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Figure 1.  Morphological characteristics of the non-adherent and the adherent 
cancer cells. a, CBS parental cells in SMEM medium (i); CBS CD133(+) cells in 
StemPro medium (ii); CBS non-adherent cells in basic serum-free medium (iii); and CBS 
non-adherent cells in SMEM medium in an ULAS plate. b, MDA-MB-231 parental cells 
in SMEM medium (i); MDA-MB-231 CD44(+) cells in StemPro medium; MDA-MB-
231 non-adherent cells in basic serum-free medium (iii); and MDA-MB-231 non-
adherent cells in SMEM medium in an ULAS plate. c, CBS CD133(+) in StemPro 
medium (i); CBS CD133(+) cells were replaced in SMEM medium for 12 h (ii), 24 h 
(iii), and 48 h (iv). 
Figure 2.  Response of the non-adherent and the adherent cancer cells to anticancer 
drugs. a, CBS cells in the different culture conditions indicated were exposed to 5-FU at 
the doses indicated for 24 h. b, MDA-MB-231 cells in the different culture conditions 
indicated were exposed to paclitaxel at the doses indicated for 24 h. c, CBS cells in the 
different culture conditions indicated were exposed to FOLFIRI (90 μM 5-FU, 28 μM 
leucovorin, and 40 nM SN-38), MMC, and paclitaxel for 24 h. The viable cells were 
determined as described in the Methods. Results are expressed as mean ± s.e.m. of 
triplicate experiments.  
Figure 3.  Response of the re-attached cancer cells to 5-FU. a, the non-adherent CBS 
CD133(+) cells were re-placed in SMEM medium to get the cells attached to the wall of 
the tissue culture plate. b, the non-adherent CBS cells in the basic serum-free medium 
were re-placed in SMEM medium to get the cells attached to the wall of the tissue culture 



































culture plate to get the cells attached to the wall of the tissue culture plate. The re-
attached cancer cells and the parental cells were exposed to 5-FU for 24 h and the viable 
cells were determined as described in the Methods. Results are expressed as mean ± 
s.e.m. of triplicate experiments. 
Figure 4.  Up-regulation of several molecules in the non-adherent cancer cells.         
a, lane 1, CBS parental cells in SMEM medium; lane 2, CBS CD133(+) cells in StemPro 
medium; lane 3, CBS non-adgerent cells in basic serum-free medium; lane 4, CBS non-
adherent cells in SMEM medium in an ULAS plate. The expression of the proteins 
indicated was determined by Western analysis. b, lane 1, CBS parental cells in SMEM 
medium; lane 2, CBS non-adherent cells in a ULAS plate; lane 3, CBS non-adherent cells 
that were re-placed in a normal tissue culture plate for 24 h; lane 4, CBS non-adherent 
cells that were re-placed in a normal tissue culture plate for 48 h; lane 5, CBS non-
adherent cells that were re-placed in a normal tissue culture plate for 72 h. The expression 
of the proteins indicated was determined by Western analysis. β-actin expression was 
used as internal controls for equal protein loading.  
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